Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: PUBPAT

It appears that a lot of share-holders need to come to terms with their investment in PTSC.

PTSC Shareholders will be very disappointed if they are expecting a traditional public relations approach.  A traditional public relations approach is not consistent with Patriot’s emerging business model.  It’s a reality!

Kalister and Fatwolit….  Ironically, in my opinion, Patriot’s new business model is centered around patent ownership  and patent licensing to manufacturers.  We are developing a model that is helping businesses take what has traditionally been an illiquid asset (an invention) and making it liquid.  In my mind, this is a healthy thing for Patriot’s investors and our overall economic system: we are driving efficiencies.

Our counterparts (competitors) in this niche do not have a public relations agenda of company advocacy. And  Patriot’s current and future partners/customers will mandate this minimalist approach around public relations. 

The types of agreements and discussions that we are entering require the highest levels of corporate confidentiality.  This emerging business model requires that Patriot gain the trust, confidence and loyalty of its clients to the extent that Patriot’s clients will trust Patriot with much or all of their existence.

At this point (12 months since our high), we need to quickly come to terms with this new reality.  And WE need to educate new investors not to expect press releases that aggressively advocate PTSC and its activities.  All investors (current and future) need to gradually come to terms with this. 

“Know what you own…”

Share
New Message
Please login to post a reply